AXSOME THERAPEUTICS I

Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Upcoming Investor Conferences

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

24 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

02 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day

21 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023

07 Sep 2023 07:03:16 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

07 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

12 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

07 Jul 2023 07:00:53 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock

30 Jun 2023 16:02:39 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock

28 Jun 2023 09:28:25 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

27 Jun 2023 20:24:44 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

01 Jun 2023 07:00:30 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

30 May 2023 07:00:54 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

08 May 2023 07:00:16 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference

03 May 2023 07:00:50 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

01 May 2023 07:00:31 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

21 Apr 2023 07:00:34 By Nasdaq GlobeNewswire